Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
December 03 2018 - 4:10PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ophthalmology and
rare diseases, today announced the appointment of Mike Fitzgerald
as vice president, human resources. Mr. Fitzgerald will serve
as a member of the Adverum leadership team and will report to Leone
Patterson, chief executive officer of Adverum.
“Mike is a valuable addition to our leadership team,” said Leone
Patterson, chief executive officer of Adverum Biotechnologies. “We
look forward to his contributions in attracting, developing and
retaining top talent as we drive the business forward.”
“I am excited to join the Adverum team,” said Mike Fitzgerald,
vice president, human resources of Adverum Biotechnologies. “I look
forward to building upon the existing Company’s core values which
support a culture focused on patients, community, integrity,
empowerment and creating new paths forward.”
Mr. Fitzgerald has over 23 years of experience leading
successful and effective teams. Prior to joining Adverum, Mr.
Fitzgerald was the Senior Vice President, Global Human Resources
for ZELTIQ Aesthetics (now Allergan). Prior to ZELTIQ, he served as
the Executive Vice President, Global Human Resources for Cepheid, a
leading company in molecular diagnostics, where he was responsible
for devising and implementing the company’s human capital strategy
and associated programs. Before joining Cepheid, he served as the
Senior Vice President of Global Human Resources at Verigy, Ltd (now
a part of Advantest Corp.). Prior to Verigy, Mr. Fitzgerald
was Vice President of Human Resources at Varian, Inc. (acquired by
Agilent Technologies), and prior to that, he held various HR roles
culminating in becoming the Global Director of HR Strategy and
Planning for Vodafone Group, plc.
Mr. Fitzgerald earned a bachelor’s degree in Political Science
from the University of California, Berkeley, a master’s degree in
Industrial Relations and Personnel Management from the University
of London’s London School of Economics and Political Science, a
master’s in Management at McGill University in Montreal, Canada as
part of the International Masters in Practicing Management Program
(IMPM), and a postgraduate diploma in applied social studies at
Trinity College, Dublin. In addition, he completed the master’s
degree in the Social Innovation program at the University of
Cambridge Judge Business School.
On the date Mr. Fitzgerald commenced his employment with
Adverum, the Company granted Mr. Fitzgerald a stock option to
purchase 190,000 shares of Adverum common stock pursuant to the
inducement grant exception under Nasdaq Rule 5635(c)(4), as an
inducement that is material to Mr. Fitzgerald entering employment
with Adverum. The option has a per share exercise price equal
to the closing sales price of Adverum’s common stock on Nasdaq on
the grant date, and will vest over four years, subject to his
continued service with Adverum.
About Adverum Biotechnologies, Inc.Adverum is a
clinical-stage gene therapy company targeting unmet medical needs
in ophthalmology and rare diseases. Adverum develops gene therapy
product candidates designed to provide durable efficacy by inducing
sustained expression of a therapeutic protein. Adverum has
collaboration agreements with Regeneron Pharmaceuticals to
research, develop, and commercialize gene therapy products for
ophthalmic diseases and Editas Medicine to explore the delivery of
genome editing medicines for the treatment of inherited retinal
diseases. Adverum’s core capabilities include clinical development,
novel vector discovery and in-house manufacturing expertise,
specifically in scalable process development, assay development,
and current Good Manufacturing Practices quality control. For more
information, please visit www.adverum.com.
Investor and Media Inquiries:
Katherine Bock
Vice President Investor Relations & Corporate Communications
Adverum Biotechnologies, Inc.
650-656-9347
kbock@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024